MED01-P2 — Gemini Stage 1 context disclosure — RAW, verbatim

Received 2026-10-06 via Danny’s paste. Answer to the identical pre-Stage-2 disclosure question sent to both researchers in their Stage 1 chats. Git only; firewall active.

Claude’s reading: Gemini searched the Drive mirror to locate the brief (contrary to brief §0b). Search snippets showed it the Probe Appendix title, header, procedural text and the §6 heading with questions Q1–Q5, plus a round-index snippet describing the two-stage design and the P2 archive audit’s existence and claim count (no archive content). This is a protocol deviation affecting the independence of Gemini’s Stage 1 map on the topics of Q1–Q5. Logged in corrections.md; disposition pending Danny.

Yes. Answering strictly from memory of this session without opening any files or tools:

1. Documents and Files Seen or Opened (Other Than the Two Attached Files) A. Internal Drive Files (Encountered in Metadata / Search Result Snippets) During the initial search to locate the brief and protocol on Google Drive, metadata and content snippets for the following project documents appeared in the tool output:

2. MED01 Round Index (P2 brief FROZEN 2026-10-03)

3. MED01-P2 Probe Appendix v1.0 FROZEN 2026-10-03 (2000–2017) — Stage 2

4. MED01-P1 §M10a Cross-Audit — Gemini — RAW (verbatim, filed 2026-10-01)

5. MED01 — Verification Log

6. MED01 Secondary Audit TEMPLATE — cross-audit (protocol v0.5 BASELINE)

7. MED01 Evidence Extraction TEMPLATE (protocol v0.5 BASELINE)

8. PROTOCOL-MEDICAL v0.5 DRAFT 2026-09-18 (baseline candidate)

9. Methodological Review: PROTOCOL-MEDICAL v0.3 DRAFT (2026-09-18)

(Note: None of these files were opened with read tools except the two designated attachments: MED01-P2 Brief v1.0 FROZEN 2026-10-03 (2000–2017) — CORE, Stage 1 and PROTOCOL-MEDICAL v0.5 BASELINE 2026-09-18 (git 7beaff6)).

B. External Literature & Web Search Results (Titles Seen or Opened) During live verification and search logging for the evidence map, the following published articles, reports, and public web documents appeared in search results or were browsed via PubMed/PMC:

• Bibliometrics & Overview:

  • A bibliometric analysis of the cannabis and cannabinoid research literature (Ng & Chang 2022, PMC9131698)

  • Bibliometric analysis of beneficial cannabis research (PMC11388674)

  • Mapping the research landscape of minor cannabinoids (PubMed 41668212)

  • Bibliometric Analysis of Cannabis sativa Research (PubMed 38252501)

  • NLM Catalog Search Guide (Scribd)

  • web query federation: Topics by Science.gov

• Basic Pharmacology & Mechanistic Trials:

  • Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses (Wilson & Nicoll 2001, Nature, PMID 11279497)

  • FAAH inhibitors in the limelight, but regrettably (Mallet, Dubray, & Dualé 2016, PMC4941643, PMID 27191771)

  • Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474 (van Esbroeck et al. 2017, Science, PMID 28596366)

  • An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845… (Huggins et al. 2012, Pain)

  • Combined inhibition of FAAH and COX produces enhanced anti… (PMC4206939)

  • The Endocannabinoid System as a Potential Therapeutic Target for Pain (PMC4115931)

  • Elevating Anandamide (AEA) by Targeting Fatty Acid Amide… (Frontiers)

• Clinical Trials (MS, Pain, Oncology, Epilepsy):

  • Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study)… (Zajicek et al. 2003, Lancet, PMID 14615106)

  • Multiple sclerosis and extract of cannabis: results of the MUSEC trial (Zajicek et al. 2012, JNNP, PMID 22791906)

  • A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex)… (Novotna et al. 2011, Eur J Neurol, PMID 21362108)

  • Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis (Collin et al. 2007, PMID 17355549)

  • A double-blind, randomized, placebo-controlled, parallel-group study of Sativex… (Collin et al. 2010, PMID 20307378)

  • Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial (Abrams et al. 2007, Neurology, PMID 17296917)

  • Smoked cannabis for chronic neuropathic pain: a randomized controlled trial (Ware et al. 2010, CMAJ, PMID 20805210, PMC2950205)

  • Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial (Ellis et al. 2009, Neuropsychopharmacology, PMID 18688212)

  • A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain (Wilsey et al. 2008, J Pain, PMID 18403272, PMC4968043)

  • Low-dose vaporized cannabis significantly improves neuropathic pain (Wilsey et al. 2013, J Pain, PMID 23237736, PMC3566631)

  • Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis (Rog et al. 2005, Neurology, PMID 16186518)

  • Multicenter, double-blind, randomized, placebo-controlled, parallel-group study… in patients with intractable cancer-related pain (Johnson et al. 2010, J Pain Symptom Manage, PMID 19896326)

  • Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain… (Portenoy et al. 2012, J Pain, PMID 22482914)

  • Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial (Devinsky et al. 2016, Lancet Neurol, PMID 26724101)

  • Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome (Devinsky et al. 2017, NEJM, PMID 28538134)

  • Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy (Porter & Jacobson 2013, PMID 24237632)

  • The case for medical marijuana in epilepsy (Maa & Figi 2014, Epilepsia, PMID 24854149)

  • A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme (Guzmán et al. 2006, Br J Cancer, PMID 16804518, PMC2360617)

  • Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study (Van Gaal et al. 2005, Lancet, PMID 15836887)

  • Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America… (Pi-Sunyer et al. 2006, JAMA, PMID 16478899)

• Harms & Cohort Studies:

  • Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study (Zammit et al. 2002, BMJ, PMID 12446534, PMC135490)

  • Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse (Allen et al. 2004, Gut, PMID 15479672, PMC1774264)

  • Persistent cannabis users show neuropsychological decline from childhood to midlife (Meier et al. 2012, PNAS, PMID 22927402, PMC3479587)

  • Association Between Marijuana Exposure and Pulmonary Function over 20 Years: The Coronary Artery Risk Development in Young Adults (CARDIA) Study (Pletcher et al. 2012, JAMA, PMID 22235088, PMC3840897)

  • Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis… (Di Forti et al. 2015, Lancet Psychiatry, PMID 25700511)

  • Effects of marijuana smoking on the lung (Tashkin 2013, PMID 23802294)

• Period Syntheses & Regulatory Documents:

  • Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review (Tramèr et al. 2001, BMJ, PMID 11440936, PMC34325)

  • Cannabinoids for Medical Use: A Systematic Review and Meta-analysis (Whiting et al. 2015, JAMA, PMID 26103030)

  • The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (NASEM 2017, Bookshelf NBK423845, PMID 28182367)

  • Cannabis-based medicines for chronic neuropathic pain in adults (Mücke et al. 2018 Cochrane review, PMC6494210, PMID 29513392)

  • UK MHRA Public Assessment Report for Sativex Oromucosal Spray (UK/H/2462/001/DC)

  • Health Canada Notice of Compliance notices for Sativex (DIN 02268571)

  • FDA approval records for Syndros (NDA 207145) and Cesamet (NDA 018677)

  • EMA European Public Assessment Report overview for Acomplia (rimonabant)

2. Mentions of “Probe Appendix”, “Stage 2”, Archive Probes, or Public Claims Yes, several items explicitly mentioned these terms:

3. MED01-P2 Probe Appendix v1.0 FROZEN 2026-10-03 (2000–2017) — Stage 2 (Drive search snippet):

   • The document title itself contained "Probe Appendix" and "Stage 2".

   • The returned snippet displayed the file header: "# MED01-P2 — PROBE APPENDIX (Stage 2)" with the subtitle "## Modern Clinical Development, 2000 – 2017 · archive probes and public claims".

   • The snippet included procedural text stating that the appendix is delivered only after Stage 1 output has been filed verbatim, noted instructions under "How to answer this appendix", referenced "archive probes", and showed a section heading "6. Archive material to be tested (§M12)" containing questions labeled Q1 through Q5.

4. MED01 Round Index (P2 brief FROZEN 2026-10-03) (Drive search snippet):

   • The snippet explicitly stated that two files were frozen together: "core brief-P2.md (Stage 1) + brief-P2-probes.md (Stage 2 Probe Appendix)".

   • It stated: "Two-stage pass (approved 2026-10-03): Stage 1 core map filed verbatim before the researcher receives the appendix; Stage 2 continues in the same researcher chat."

   • It also noted: "P2 archive audit Required — filed 2026-09-26 (archive-audit-P2.md): moderate overlap; 72 claims C11–C82; 12 neutral questions → appendix Q1–Q12."

5. brief-P2.md (the core brief attachment itself):

   • In §0a, §5, and §6–7, the text explicitly referenced "Stage 2 — probe addendum", "Probe Appendix", and noted that "Archive probes and public claims → Probe Appendix (Stage 2)" are delivered after the Stage 1 core map has been filed.

As disclosed at the top of the Stage 1 submission, all such metadata and snippet contents visible during initial retrieval were set aside and disregarded to preserve complete analytical independence for the Stage 1 evidence map.